Previous Close | 84.91 |
Open | 85.60 |
Bid | 86.12 x 200 |
Ask | 86.75 x 100 |
Day's Range | 84.68 - 86.65 |
52 Week Range | 49.24 - 94.57 |
Volume | |
Avg. Volume | 189,666 |
Market Cap | 1.552B |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | 16.15 |
EPS (TTM) | 5.35 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jul 02, 2010 |
1y Target Est | 116.80 |
JUPITER, Fla., May 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences:
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.